Your Cart is Empty
Start shopping
CIMZIA® (Non-English)
Tier
| Packs | Discount (%) | For Each |
|---|---|---|
| 1 - 3 | — | $1,599.00 |
| 4 - 10 | 6.25 % | $1,499.00 |
| 11 - 20 | 6.88 % | $1,489.00 |
| 21+ | 7.5 % | $1,479.00 |
Shop with Confidence: 100% Authentic Products
All products are sourced from trusted suppliers and come with original manufacturer LOT numbers for identification and traceability.
Product description
CIMZIA® is a prescription subcutaneous biologic medication that functions as a tumor necrosis factor (TNF) blocker. It is used in adults for the treatment of inflammatory conditions, including active rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and moderate to severe plaque psoriasis. CIMZIA® helps manage these conditions by targeting TNF activity, which plays a role in inflammation and immune system responses.
Discover the full range of products when you buy CIMZIA® online and access available wholesale purchasing options.
FAQ
CIMZIA® is a tumor necrosis factor-alpha (TNF-α) inhibitor used primarily to treat moderate to severe rheumatoid arthritis in adult patients. It contains certolizumab pegol, a PEGylated, recombinant, humanized Fab’ fragment expressed in Escherichia coli that selectively binds to TNF-α. CIMZIA® is especially suitable for patients who do not respond adequately to conventional disease-modifying antirheumatic drugs (DMARDs), including methotrexate (MTX). It can also be used as monotherapy in MTX-intolerant patients. It has shown efficacy in reducing joint damage and improving physical function when used in combination with MTX.
CIMZIA® is administered subcutaneously and must be started by experienced healthcare providers. The treatment begins with an initial loading dose, followed by maintenance therapy.
- Initial dose: 400 mg at weeks 0, 2, and 4 (2 × 200 mg injections)
- Maintenance dose: 200 mg every 2 weeks
- Route: Subcutaneous (thigh or abdomen)
- Formulation: 1 mL ready-to-use prefilled syringe
CIMZIA® is indicated for adults with active moderate-to-severe rheumatoid arthritis, particularly in cases with inadequate response to DMARDs. It can be used in combination with MTX or as monotherapy when MTX is not suitable.
Contraindications:
- Hypersensitivity to certolizumab pegol or excipients
- Active tuberculosis, sepsis, or other serious infections
- Moderate to severe heart failure (NYHA class III/IV)
Common Side Effects:
- Infections (e.g., respiratory, urinary tract)
- Injection site reactions
- Headache
- Nausea
Serious Side Effects:
- Sepsis, tuberculosis, malignancies
- Lupus-like syndrome
- Demyelinating disorders
- Hematologic abnormalities (e.g., pancytopenia)
Each prefilled syringe contains:
- Certolizumab pegol 200 mg (active ingredient)
- Excipients: Sodium acetate (1.36 mg), Sodium chloride (7.31 mg), Water for injection
Each box includes:
- 2 prefilled syringes (1 mL each containing 200 mg certolizumab pegol)
- 2 alcohol pads
- The syringe is latex-free
CIMZIA® may cause a range of adverse effects, from mild to serious.
Common adverse effects:
- Infections (bacterial, viral, fungal)
- Headache, rash, injection site erythema
- Elevated liver enzymes, hypertension
Uncommon but serious effects:
- Reactivation of hepatitis B
- Tuberculosis, opportunistic infections
- Heart failure exacerbation
- Autoimmune phenomena (e.g., lupus, vasculitis)
- Malignancies, including lymphoma and skin cancer
Proper storage is essential for maintaining product integrity.
- Temperature: Store at 2–8°C (refrigerated)
- Do not freeze
- Protect from light
- Keep in the original packaging
- Single-use only; discard after use
Doctor Medica sources products exclusively through authorized distributors and established procurement channels. Products are verified as genuine, and supplied in the original packaging with their seal intact. Learn more about how we guarantee product authenticity, sourcing compliance, and traceable delivery to our clients.
